
Metformin (500mg) + Sitagliptin (50mg)
Rayax Drug India
Sitagliptin 50mgPack Size
Strip of 15 tablets
Price
Save ₹2
that's 1% off!
Active composition
+1 more active ingredient
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Sitagliptin inhibits DPP-4, increasing incretin levels, which stimulate insulin release and reduce glucagon secretion.
Medical applications
Lupisit M 50mg/500mg Tablet is a combination oral antidiabetic medication containing Sitagliptin 50mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. The synergistic action of these agents helps achieve better glycemic regulation than monotherapy. Lupisit M is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on either component alone or those already receiving combination therapy. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, which often subside with continued use. Regular monitoring of renal function and blood glucose levels is recommended during therapy to minimize risks and optimize treatment outcomes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Lupisit M 50mg/500mg Tablet during pregnancy is not available. Please consult your doctor.
High Risk
Lupisit M 50mg/500mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Lupisit M 50mg/500mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Lupisit M 50mg/500mg Tablet may be needed. Please consult your doctor. Use of Lupisit M 50mg/500mg Tablet is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
Lupisit M 50mg/500mg Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Lupisit M 50mg/500mg Tablet

Sitagliptin (50mg) + Metformin (500mg)
Rayax Drug India
Sitagliptin 50mgPack Size
Strip of 15 tablets
Price
Save ₹2
that's 1% off!
Active composition
+1 more active ingredient
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Sitagliptin inhibits DPP-4, increasing incretin levels, which stimulate insulin release and reduce glucagon secretion.
Medical applications
Lupisit M 50mg/500mg Tablet is a combination oral antidiabetic medication containing Sitagliptin 50mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. The synergistic action of these agents helps achieve better glycemic regulation than monotherapy. Lupisit M is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on either component alone or those already receiving combination therapy. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, which often subside with continued use. Regular monitoring of renal function and blood glucose levels is recommended during therapy to minimize risks and optimize treatment outcomes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Lupisit M 50mg/500mg Tablet during pregnancy is not available. Please consult your doctor.
High Risk
Lupisit M 50mg/500mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Lupisit M 50mg/500mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Lupisit M 50mg/500mg Tablet may be needed. Please consult your doctor. Use of Lupisit M 50mg/500mg Tablet is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
Lupisit M 50mg/500mg Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Lupisit M 50mg/500mg Tablet













